- Home
- LCFY vs VIVS Comparison
LCFY vs VIVS Comparison
Compare LCFY & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- VIVS
- Stock Information
- Founded
- LCFY 2009
- VIVS 2007
- Country
- LCFY Australia
- VIVS United States
- Employees
- LCFY N/A
- VIVS N/A
- Industry
- LCFY
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCFY
- VIVS Health Care
- Exchange
- LCFY Nasdaq
- VIVS Nasdaq
- Market Cap
- LCFY 5.9M
- VIVS 5.0M
- IPO Year
- LCFY 2022
- VIVS N/A
- Fundamental
- Price
- LCFY $6.95
- VIVS $2.24
- Analyst Decision
- LCFY
- VIVS
- Analyst Count
- LCFY 0
- VIVS 0
- Target Price
- LCFY N/A
- VIVS N/A
- AVG Volume (30 Days)
- LCFY 5.4M
- VIVS 70.9K
- Earning Date
- LCFY 08-05-2025
- VIVS 08-05-2025
- Dividend Yield
- LCFY N/A
- VIVS N/A
- EPS Growth
- LCFY N/A
- VIVS N/A
- EPS
- LCFY N/A
- VIVS N/A
- Revenue
- LCFY $2,668,385.00
- VIVS $144,000.00
- Revenue This Year
- LCFY N/A
- VIVS $42.38
- Revenue Next Year
- LCFY N/A
- VIVS $15.42
- P/E Ratio
- LCFY N/A
- VIVS N/A
- Revenue Growth
- LCFY N/A
- VIVS 32.11
- 52 Week Low
- LCFY $2.51
- VIVS $1.41
- 52 Week High
- LCFY $13.98
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- LCFY 67.75
- VIVS N/A
- Support Level
- LCFY $4.50
- VIVS N/A
- Resistance Level
- LCFY $6.85
- VIVS N/A
- Average True Range (ATR)
- LCFY 0.65
- VIVS 0.00
- MACD
- LCFY 0.20
- VIVS 0.00
- Stochastic Oscillator
- LCFY 98.61
- VIVS 0.00
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.